International Mouse Phenotyping Consortium (IMPC) & INFRAFRONTIER: Global and European Infrastructures IMPC and INFRAFRONTIER Towards the Deciphering of Gene Functions for Human Health
18. 10. 2022, 13:00
satellite events

European and world-wide research infrastructures provide comprehensive resources regarding gene function in physiology and disease. The infrastructures are used globally to model human biology and disease enabling therapeutic discovery and precision medicine.


Organiser: International  Mouse Phenotyping Consortium (IMPC) & INFRAFRONTIER in cooperation with  BBMRI, EATRIS, and ECRIN (EU-AMRI)

The International Mouse Phenotyping Consortium (IMPC) was established as a global consortium of genetic centres with the expertise and facilities to undertake genome-wide genome-phenome studies on a large-scale. The key aim of the IMPC is to create a comprehensive catalogue of mammalian gene function to describe the genetic basis of diseases. IMPC has worked as a global infrastructure already for 10 years and recently updated its strategic goals for the 2021-2030 period.

INFRAFRONTIER is the European Research Infrastructure which provides the biomedical research community with the tools needed to unravel the role of gene function in human disease.

The satellite event aims to showcase the scientific achievements and impact on various areas of human disease research and share its experience of the management of the scientific data produced, and describe how IMPC and INFRAFRONTIER with their resources and technologies strive together with medically focused RIs EATRIS, BBMRI, and ECRIN to establish a novel transformative European platform, which will provide state-of-the-art equipment, technologies, and expertise to clinicians, basic researchers and companies working on innovative curative therapies for human diseases.

IMPC - Worldwide infrastructure for transformative insights into the genetic basis of disease (Steve Brown/ Radislav Sedlacek)

Additional presentation on:

- rare disease & therapies;
- precise medicine models:
- towards gene therapy.


  • BBMRI-ERIC  fostering genomic medicine from patients’ consent via research to clinical application (Jens K. Habermann)
  • Genome, phenome and exposome as the three pillars of personalised medicine (Jacques Demotes, ECRIN)
  • Accelerating the development of Advanced Therapy Medicinal Products, a Research Infrastructure perspective (David Morrow, EATRIS)
  • INFRAFRONTIER: Pan-European Research infrastructure for modelling human diseases (Martin Hrabe de Angelis)
  • Inauguration of the travelling & virtual exhibition “Gene Age” – AV21 Strategy Programme on “Gene Therapy (R. Sedlacek, CCP)